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We sought to answer whether one-month duration of dual antiplatelet therapy (DAPT) is 
safe after elective drug-coated balloon only (DCB) angioplasty.   
Background:  
The duration of DAPT after elective DCB was called into question after the ESC Focused 
DAPT Update of 2017. Until then, a one-month duration of DAPT was considered safe by 
national consensus groups (German, Italian and Chinese) supported by data from 
prospective worldwide registries. 
The ESC Guidelines recommended a 6-month duration of DAPT based on evidence from in-
stent restenosis randomized controlled trials only.  
 
Methods: 
Retrospective, real-world population, single-center analysis was conducted from January 1st, 
2012 to March 31st, 2017 from a high-volume, tertiary PCI cente. All patients who received a 
one-month duration of DAPT after elective DCB angioplasty were included. We identified a 
primary composite outcome of cardiac death, myocardial infarction and target lesion 
revascularisation at 6-months. 
 
Results:  
This included 303 patients (78.5% male) with a mean age of 67±12.5. This incorporated 
86.1% de novo lesions and 56.5% non-small (3mm diameter) coronary arteries treated. 
There were no reported outcomes of lesion thrombosis, target vessel MI, target lesion 
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revascularization or cardiac death at 6-months. There were two (0.6%) non-target vessel 
MIs and one (0.3%) non-cardiac death. 
 
Conclusion:  
One-month duration of DAPT appears safe after elective DCB-only angioplasty, highlighting 
this strategy for patients at high-risk of bleeding. These results also show favorable clinical 
outcomes for de novo coronary artery disease and non-small coronary arteries treated with 





A lot of interest has been generated lately about the use and safety of DCB angioplasty 
focused mainly on peripheral intervention1,2,3,4. However, the use of drug coated balloons 
(DCB) for coronary intervention has also been steadily increasing over the last few years and 
as more studies report encouraging results5,6, DCB-only angioplasty for coronary disease is 
expected to increase further. Original recommendations for DCB use came from the German 
Consensus Group 7,8 which also addressed the duration of dual antiplatelet therapy following 
DCB; stating that four weeks  of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel 
were deemed appropriate in patients with stable coronary disease with monotherapy life-
long thereafter. The evidence for this came from small to moderate randomized controlled 
studies and large prospective worldwide registries. This was followed by the Italian Society of 
Interventional Cardiology9 and the Chinese Expert Group10, both supporting the German 
recommendation of  one-month DAPT for stable coronary disease.  
 
However, The European Society of Cardiology (ESC) Focused Update on DAPT 2017 took a 
different view and advocated a  6 month duration  of DAPT in DCB angioplasty11. This 
recommendation was supported by circumstantial evidence from three randomized control 
trials comparing DCB with drug eluting stents (DES) for in-stent restenosis only, whilst no DCB 
studies in de novo coronary intervention were included. In these three studies the duration 
of DAPT varied from 3 to 12 months. 12–14 In RIBS-IV DAPT of a 3-month duration was given in 
the DCB arm, PEPCAD China ISR gave a 12-month duration of DAPT and ISAR-DESIRE-3 gave a 
6-month minimum duration of DAPT. Of significance, is that bleeding events were not 
addressed in any of these three studies.   
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Following the publication of the ESC Focused Update 2017, there has been data from two 
important studies in de novo coronary disease. Firstly, the Basket-Small 2 was a randomized 
control trial comparing DCB with DES for small vessel de novo coronary disease and gave a 
one-month duration of DAPT to the DCB arm in all patients with stable coronary disease5. 
Secondly, Debut, a randomized trial comparing BMS to DCB in patients with high bleeding 
risk, also gave a one-month duration of DAPT for DCB angioplasty; thus suggesting that a full 
6 month course of DAPT might not be necessarily required when a DCB-only approach is used. 
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Although DCB angioplasty holds  a class 1 recommendation by the ESC for in-stent restenosis 
angioplasty,  there is now increasing evidence supporting the use of DCB for de novo coronary 
disease. 5 As this use is projected to expand further we felt it was important to interrogate 
our existing DCB registry, a dedicated registry at the Norfolk and Norwich University Hospital 
including all patients who receive DCB-only angioplasty, to identify if a shorter one-month 
DAPT is safe in routine clinical practice. This is, to our knowledge, the first study using a real-
world population to specifically answer the question regarding the safety of one-month DAPT 
in DCB-only angioplasty.  
 
Materials and Methods 
We retrospectively identified all patients from our local registry from January 1st, 2012 to 31st 
March 2017 who had undergone elective DCB-only angioplasty for stable coronary artery 
disease and received one-month DAPT. Institutional approval was obtained from Norfolk and 
Norwich University Hospital, UK and in line with other research of retrospective nature the 
need for patient consent was waived. 
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We included both de novo lesions and in-stent restenosis (ISR) lesions. Clinical outcomes were 
obtained through electronic clinical records and up-to-date mortality data was obtained from 
the Demographic Batch Service Bureau of the Health and Social Care Information Centre, a 
National database where all deaths are recorded. All patients who had a concomitant use of 
oral anticoagulant were excluded, as were those who underwent a staged procedure 
following acute coronary syndrome, with a pre-mandated 12-month duration of DAPT. 
We defined a 6-month device-oriented primary composite end-point of cardiovascular death, 
myocardial infarction (not clearly attributed to a non-target vessel) and target lesion 
revascularization (clinically driven) in keeping with the ARC-2 recommendation for device 
outcome reporting. 15 We chose the 6-month cutoff point following the ESC guidelines 
recommended cessation period for DAPT, as after this time monotherapy would have 
continued with the ESC guidelines also.  
Myocardial infarction was defined as presence of chest pain or ischemic ECG changes with a 
rise in cardiac enzyme troponin and with no other vessel clearly identified as the culprit vessel. 
Cardiac death was defined in accordance with the 2017 Consensus Report on Cardiovascular 
and Stroke Endpoint Definitions for Clinical Trials 16 and included:   
1) death resulting from an acute myocardial infarction (AMI), 
2) sudden cardiac death, 
3) death due to heart failure (HF), 
4) death due to stroke,  
5) death due to cardiovascular (CV) procedures, and 
6) death due to CV hemorrhage. 
Secondary outcomes included: non-cardiac death, lesion thrombosis and non-target vessel 
myocardial infarction.  
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Lesion thrombosis was defined as acute (<1 day), sub-acute (1 to 30 days), and late (>30 days) 
and defined in parallel to the ARC guidelines on Stent Thrombosis. 17 
 
All procedural elements were at the discretion of the operators with practice based on 
guidelines for DCB angioplasty as previously reviewed. 18  All adverse events were 





A total of 303 patients were identified with 361 lesions treated with DCB-only PCI electively 
for coronary disease and who received DAPT for one month only.  The cohort included mainly 
male patients (78.5%), with a mean age of 67±12.5 with 39.6% having had prior PCI, 9.6% 
having had prior CABG and other risk factors as outlined in table 1. These findings are in 
keeping with contemporaneous stable angina studies. 12, 13, 14   
 
Table 1: Patient Characteristics 
 
Following one-month DAPT all patients continued with aspirin monotherapy thereafter. Some 
96.4% received aspirin and clopidogrel for one month, 2.2% received aspirin and ticagrelor 
and 1.4% received aspirin and prasugrel. The use of ticagrelor or prasugrel was only due to 




Lesion and procedural characteristics 
 
Of 361 lesions treated, 86.1% were de novo lesions, the remaining 13.9% being in-stent 
restenosis lesions. The majority of lesions treated were left anterior descending artery 
(48.2%), 24.1% circumflex, 23% right coronary artery, 3.6% left main stem and 1.1% vein 
grafts. The DCBs used as follows: 143 (39.6%) were SeQuent Please (B Braun Melsungen AG, 
Germany), 186 (51.5%) were SeQuent Please NEO (B Braun Melsungen AG, Germany), 31 
(8.6%) were IN.PACT Falcon (Medtronic, Inc., Santa Rosa, California, USA) and 1 (0.3%) were 
DIOR (Eurocor GmbH, Germany). Lesion complexity was assessed using The American College 
of Cardiology/ American Heart Association (ACC/AHA) Task Force on Assessment of 
Diagnostic and Therapeutic Cardiovascular Procedures classification system,19 and is 
summarized in Table 2.  
Some 43.5% of lesions were small vessels (with DCB diameter of <3mm used) whilst 56.5% 
were large vessel with DCB diameter used was  3mm.  
 
Table 2: Lesion Characteristics 
 
Clinical outcomes 
Follow up at 6 months was 100% with patient outcomes shown in table 3. There were no 
reported occurrences of lesion thrombosis, target lesion MI or cardiac death at 6 months. 
There were no TLRs at 6-months. There was 1 (0.3%) death at 50 days due to end stage renal 
failure. There were 2 (0.6%) non-target vessel MIs, one at 49 days and one at 156 days. On 
both follow-up angiograms, the target lesion result was acceptable.  
Table 3: Outcomes 
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Discussion  
DCB angioplasty currently holds a class Ia recommendation for its use in ISR in accordance 
with the current ESC Guidelines 11, although there is increasing evidence to support its use 
for de novo coronary disease. 5,4  With this use of DCB angioplasty predicted to increase, it is 
important to determine a safe duration for DAPT for elective procedures, a gap in the 
literature inadvertently highlighted by the ESC Focused Update on DAPT. Although 
recommending a 6-month duration of DAPT, the evidence studied to reach this decision was 
only from ISR RCTs and did not incorporate any de novo DCB literature, whilst previous 
Consensus Groups and National Societies had recommended a one-month duration of DAPT 
for DCB angioplasty in stable coronary disease. A recent literature search and sub-group 
analysis presented by Kleber et al. 20 reviewing all published RCTs and registries including de 
novo coronary disease suggested a one-month duration of dual antiplatelet therapy after 
DCB angioplasty was safe. This has been furthermore consolidated with recent RCTs which 
gave a one-month duration of DAPT for stable CAD.  5, 4 
We sought to answer whether a one-month duration of DAPT for stable coronary disease is 
safe. We conducted a retrospective analysis, using a real-world population, incorporating 
361 lesions in 303 patients, of which 85.9% were de novo lesions. We found that one-month 
DAPT duration was safe with regards to lesion thrombosis, target lesion MI, TLR and cardiac 
death, with zero adverse outcomes at 6 months. This extends the evidence from current 
trials to include de novo coronary anatomy, and importantly, also incorporates data on non-
small coronary vessels (as 56.5% in our cohort were 3mm), which to this point was an 
evidence-free area. As such, our results are expanding on the previous work by Kleber et al., 
20 and the Basket-Small RCT 5.  
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Of note, our clinical outcomes are reporting significantly lower rates of MACE than other 
real-life registry data. 21 Several potential explanations for the difference in outcome include 
a shorter clinical end-point (6-month versus 9-month), smaller numbers, increased operator 
skill in a single-center doing a large volume of DCB only angioplasty  and improved technique 
for DCB delivery. These improved clinical outcomes may be an indicator that due to 
improved technique and operator skill with DCB techniques, clinical outcomes with DCB only 
angioplasty are better than initially reported in registry data.  
Acknowledging that bleeding rates after successful PCI are independently associated with a 
higher morbidity and mortality rate 22  and a shorter duration of DAPT has been shown to be 
beneficial in risk reduction in those with higher bleeding risk in prospective registry studies 
23 24, we believe that our data provides compelling evidence that can potentially extend the 
role of DCB angioplasty to those patients at high bleeding risk by enabling a shorter but safer 
one-month DAPT.  
 
Limitations 
Our study consists of only a small number of ISR lesions and subsequently our conclusions 
on that sub-group are less robust and a separate analysis with larger numbers may be 
warranted given the duration of DAPT in current RCT evidence ranges from 3-12 months.  
In addition, selection bias and confounding errors are inherent limitations of a retrospective, 
single-center analysis. However, to limit this, we included all consecutive patients in our 
registry with a catchment area of over one million people. Furthermore, our patient 
demographics are similar to other contemporaneous DES studies in the UK 12, 14 ,13 indicating 
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that significant selection bias was unlikely. Finally, as we undertake more than 40% of our 
PCI with a DCB-only approach, we feel this would have minimized bias.  
 
Conclusion 
A one-month only duration of DAPT following elective DCB-only angioplasty appears safe, 
specifically for de novo coronary disease, in both small and non-small vessel disease and is the 
first report of real-world data on this topic. Our data further supports the use of DCB-only 
angioplasty for all sub-groups, with zero adverse device-related outcomes across all specified 
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